Consumer medicine information

Copaxone 40 mg/mL

Glatiramer acetate

BRAND INFORMATION

Brand name

Copaxone Prefilled Syringe

Active ingredient

Glatiramer acetate

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Copaxone 40 mg/mL.

SUMMARY CMI

COPAXONE® 40 mg/mL Pre-filled Syringe

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using COPAXONE?

COPAXONE contains the active ingredient glatiramer acetate. COPAXONE is used for the management of relapsing forms of Multiple Sclerosis (MS).

For more information, see Section 1. Why am I using COPAXONE? in the full CMI.

2. What should I know before I use COPAXONE?

Do not use if you have ever had an allergic reaction to glatiramer acetate or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use COPAXONE? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with COPAXONE and affect how it works.

For more information, see Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use COPAXONE?

  • The recommended dose of COPAXONE is one 40 mg/mL pre-filled syringe (1mL) injected three times a week and at least 48 hours apart.
  • COPAXONE 40 mg/mL is given by an injection into the fatty layer under the skin (subcutaneous injection).

More instructions can be found in Section 4. How do I use COPAXONE? in the full CMI.

5. What should I know while using COPAXONE?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using COPAXONE.
Things you should not do
  • Do not use more than the recommended dose unless your doctor tells you to.
Looking after your medicine
  • Keep COPAXONE 40 mg/mL pre-filled syringes in the refrigerator at 2°C to 8°C.
  • Keep COPAXONE 40 mg/mL in the pack until it is time to use it. Protect from direct light.

For more information, see Section 5. What should I know while using COPAXONE? in the full CMI.

6. Are there any side effects?

Common side effects: Immediate Post Injection Reaction which includes the following symptoms - reddening of the face and/or neck, chest pain or tightness, feeling your heart beat quickly (heart palpitations), anxiety and difficulty in breathing.

Serious side effects: Symptoms of an allergic reaction that include - swelling of the face, lips, mouth or throat, which may cause difficultly in swallowing or breathing, hives, chest pain, trouble breathing and severe pain, redness or swelling at the injection site that does not go away.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

COPAXONE® 40 mg/mL Pre-filled Syringe Solution for Injection

Active ingredient(s): glatiramer acetate

Consumer Medicine Information (CMI)

This leaflet provides important information about using COPAXONE. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using COPAXONE.

Where to find information in this leaflet:

1. Why am I using COPAXONE?
2. What should I know before I use COPAXONE?
3. What if I am taking other medicines?
4. How do I use COPAXONE?
5. What should I know while using COPAXONE?
6. Are there any side effects?
7. Product details

1. Why am I using COPAXONE?

COPAXONE contains the active ingredient glatiramer acetate. The exact mechanism of how COPAXONE works is unknown, it is thought that COPAXONE works by changing the immune processes that are believed to be responsible for the disease.

COPAXONE is used for the management of relapsing forms of Multiple Sclerosis (MS).

COPAXONE may also be used in patients who, for the first time, have experienced symptoms and have MRI changes that indicate a high risk for development of MS. Your doctor will rule out any other reasons which could explain these symptoms before you are treated.

The cause of MS is not yet known. MS affects the brain and spinal cord. In MS, the body's immune system reacts against its own myelin (the ‘insulation’ surrounding nerve fibres). In relapsing forms of MS, people can have ‘exacerbations’ from time to time (e.g. blurred vision, weakness in the legs or arms, or loss of control of bowel or bladder function). These are followed by periods of recovery.

COPAXONE has been shown to be effective in reducing the number of relapses in patients with relapsing remitting MS. Although it is not a cure, patients treated with COPAXONE 40mg/mL generally find that they will experience fewer relapses.

2. What should I know before I use COPAXONE?

Warnings

Copaxone can cause severe allergic reactions, some of which may be life-threatening. These reactions may occur shortly after administration, even months or years after starting treatment and even if previous administrations were without allergic reactions. The signs and symptoms of allergic reactions may overlap with post-injection reactions.

Do not use COPAXONE if:

  • you are allergic to glatiramer acetate, or any of the ingredients listed at the end of this leaflet.
  • Always check the ingredients to make sure you can use this medicine.

Check with your doctor if you:

  • have any other medical conditions including asthma and liver disease
  • take any medicines for any other condition
  • have ever had asthma
  • have a history of severe allergic reactions
  • have ever had a liver injury
  • plan to have surgery

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Limited data in humans showed no negative effects of glatiramer acetate on breastfed infants.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

Children

Do not give COPAXONE to children. There is no experience with its use in children under 12 years of age.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with COPAXONE and affect how it works.

Some medicines may interfere with the absorption of COPAXONE.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect COPAXONE.

4. How do I use COPAXONE?

How much to use

  • The recommended dose of COPAXONE is one 40 mg/ mL pre-filled syringe (1mL) injected three times a week and at least 48 hours apart.
  • Follow the instructions provided and use COPAXONE until your doctor tells you to stop.

When to use COPAXONE

  • COPAXONE 40 mg/mL should be used, if possible, at the same time and on the same three days each week (for example, Monday, Wednesday and Friday) at least 48 hours apart.
  • Do not change the dose or dosing schedule or stop using COPAXONE without talking to your doctor.

How to use COPAXONE

  • COPAXONE 40 mg/mL is given by an injection into the fatty layer under the skin (subcutaneous injection).
  • Many people with MS learn to give themselves the injection or have it given by a carer.
  • Self-injection needs to be taught and practiced. It is important that a qualified healthcare professional supervises your first injection.
  • Your doctor may teach you to self-inject or arrange for an MS education nurse to do so.
  • You may have a friend attend the injection training session as your assistant. Especially when you first start giving yourself injections, your assistant should be with you.
  • Talk to your doctor or your nurse or telephone 1800 288 382 in Australia or 0800 800 097, in New Zealand for more information.
  • A self-injection device is available in Australia by telephoning 1800 288 382.
  • After being taught to self-inject, you can refer to this leaflet for step-by-step instructions about how to prepare and inject COPAXONE 40 mg/mL.
  • The following instructions explain how to inject COPAXONE 40 mg/mL yourself.
  • Do not attempt self-injection until you are confident that you understand how to inject yourself.
  • Please read these instructions carefully.

Before you inject

  • COPAXONE 40 mg/mL pre-filled syringe is pre-mixed and ready for you to use.
  • Make sure that the blister with the syringe inside is taken out of the refrigerator for 20 minutes before you use it.

It is important that the solution is at room temperature when you inject it. If you need to delay your injection, return the blister to its package in the refrigerator.

Always inspect COPAXONE solution in the pre-filled syringe before you use it. Do not inject the solution if it is cloudy or has particles in it.

Gathering the Materials

Gather the following items on a towel that is laid on a flat surface in a clean, well-lit area:

  • One blister with COPAXONE 40 mg/mL pre-filled syringe (at room temperature - as described above)
  • A dry cotton ball
  • Disposal unit for used syringes

Wash and dry your hands. Do not touch your hair or skin afterwards. This will help prevent infection.

Deciding where to Inject

There are seven injection areas on your body; arms, thighs, back of the hips and stomach (belly). Within each injection area there are multiple injection sites (Figure 1).

Rotate the injection sites within an area.

You should not use any site more than once a week. Choose a different site for each injection. This will reduce the likelihood of irritation, pain or loss of fatty tissue (lipoatrophy) at the site of injection.

Marking a calendar will help you keep track of the sites you have used each week.

Do not inject in an area of skin that is bruised, inflamed or damaged.

Giving yourself the injection

  1. Remove the syringe from its protective blister by peeling back the blister foil.
  2. Pick up the syringe as you would a pencil, using the hand you write with. Remove the plastic cover from the needle.
  3. Pinch about a 5 cm fold of skin between thumb and index finger.
When you inject in the upper back portions of your arms, it is not possible to pinch 5 cm of skin with one hand and inject yourself with the other hand. Ask your doctor / nurse for instruction on how to use these areas.

  1. Insert the needle into the 5 cm fold of skin. It may help to steady your hand by resting the heel of your hand against your body.

  1. When the needle is all the way in, release the fold of skin.
  2. Inject the medication by holding the syringe steady while pushing down on the plunger until the syringe is empty. The injection should take just a few seconds.
  3. Pull the needle straight out.
  4. Press a dry cotton ball on the injection site for a few seconds, but do not massage it.
  5. Dispose of the pre-filled syringe in a safe hard-walled container, according to your doctor's instructions and the laws of your state (if any). Ask your doctor or pharmacist for advice if you are in doubt.

Do not reuse the pre-filled syringe. Each pre-filled syringe should be used only for one injection.

Some patients may experience a side-effect known as the Immediate Post Injection Reaction. See Section 6. Are there any side effects?

If you forget to use COPAXONE

COPAXONE should be used regularly at the same time and on the same three days each week. If you miss your dose at the usual time, you should take your next dose as soon as you remember or are able to take it, then skip the following day. If possible, you should return to your regular administration schedule the following week.

Do not take a double dose to make up for the dose you missed.

If you use too much COPAXONE

If you think that you have used too much COPAXONE, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26 in Australia or 0800 764 766 in New Zealand), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while using COPAXONE?

Things you should do

If you are about to be started on any new medicine, tell your doctor and pharmacist that you are using COPAXONE 40 mg/mL.

If you plan to have surgery that needs a general anaesthetic, tell your doctor or dentist that you are using this medicine.

If you become pregnant while you are using this medicine, talk to your doctor to discuss whether ongoing COPAXONE treatment is appropriate for you.

Remind any doctor, dentist or pharmacist you visit that you are using COPAXONE.

Things you should not do

  • Do not use more than the recommended dose unless your doctor tells you to.
  • Do not give this medicine to anyone else, even if they have the same condition as you.

Looking after your medicine

  • Keep COPAXONE 40 mg/mL pre-filled syringes in the refrigerator at 2°C to 8°C.
  • Keep COPAXONE 40 mg/mL in the pack until it is time to use it. Protect from direct light.
  • In the event of refrigeration being unavailable, COPAXONE 40 mg/mL may be stored below 25°C on one occasion for up to one month.
  • COPAXONE 40 mg/mL must not be frozen. Do not place in the freezer or freezing compartment of a refrigerator.

Follow the instructions in the carton on how to take care of your medicine properly.

Store it in a cool dry place away from moisture, heat or sunlight; for example, do not store it:

  • in the bathroom or near a sink, or
  • in the car or on window sills.

Keep it where young children cannot reach it.

When to discard your medicine

Ask your doctor or nurse about obtaining a “sharps container”.

After use, place all used syringes and needles in a hard-walled plastic container, such as a liquid laundry detergent container or sharps container.

It is very important that you keep the cover of the container tightly shut and that you store it out of the reach of children. When the container is full, check with your doctor or nurse about proper disposal.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effectsWhat to do
Skin related:
  • pain, redness, itching, hardening of the skin or an infection at the site where you have injected yourself
Immediate Post Injection Reaction which includes the following symptoms:
  • reddening of the face and/or neck,
  • chest pain or tightness,
  • feeling your heart beat quickly (heart palpitations),
  • anxiety and difficulty in breathing.
  • allergic reaction (anaphylactic)
Gut related:
  • nausea (feeling sick)
  • constipation
Symptoms related to liver injury:
  • yellowing of the skin or eyes
  • dark urine
  • abdominal pain
  • vomiting
  • loss of appetite
  • weight loss
  • unusual tiredness
Other:
  • pain in the joints
  • sore muscles
  • feeling of weakness
  • dizziness
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
Symptoms of an allergic reaction:
  • swelling of the face, lips, mouth or throat, which may cause difficultly in swallowing or breathing
  • hives
  • chest pain
  • trouble breathing
  • severe pain, redness or swelling at the injection site that does not go away.
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What COPAXONE contains

Active ingredient
(main ingredient)		Glatiramer acetate 40 mg/mL
Other ingredients
(inactive ingredients)		Mannitol
Water for Injections

Do not take this medicine if you are allergic to any of these ingredients.

What COPAXONE looks like

COPAXONE 40 mg/mL is a clear colourless solution supplied in 1mL glass single use pre-filled syringes fitted with a staked ½ inch needle (Aust R 218615).

COPAXONE 40 mg/mL pre-filled syringe is supplied in a box of 12 blister packed pre-filled syringes.

Who distributes COPAXONE

COPAXONE 40 mg/mL is distributed in Australia by:

Teva Pharma Australia Pty Ltd
Level 1, 37 Epping Road
Macquarie Park NSW 2113

COPAXONE 40 mg/mL is distributed in New Zealand by:

Teva Pharma (New Zealand) Limited
PO Box 128 244
Remuera
Auckland 1541

This leaflet was prepared in December 2024.

® Copaxone is a registered trademark of Teva Pharmaceuticals Industries Ltd.

Published by MIMS February 2025

BRAND INFORMATION

Brand name

Copaxone Prefilled Syringe

Active ingredient

Glatiramer acetate

Schedule

S4

 

1 Name of Medicine

Glatiramer acetate.

2 Qualitative and Quantitative Composition

Copaxone 40 mg/mL contains 40 mg of glatiramer acetate.
Glatiramer acetate, the active ingredient in Copaxone 40 mg/mL, is the acetate salt of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine and L-lysine with an average molar fraction 0.141, 0.427, 0.095 and 0.338, respectively.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Copaxone is a clear, colourless solution for injection, in a pre-filled syringe.

4 Clinical Particulars

4.1 Therapeutic Indications

Reduction of the frequency of relapses in patients with relapsing remitting multiple sclerosis.
Treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent MRI lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

4.2 Dose and Method of Administration

The only recommended route of administration of Copaxone injection is by the subcutaneous route. Copaxone should not be administered by the intravenous or intramuscular routes.
The recommended dosage in adults is one subcutaneous injection of 1 mL Copaxone 40 mg administered three times a week and at least 48 hours apart. This corresponds to one Copaxone 40 mg/mL pre-filled syringe per administration.

Method of administration.

Sites for self-injection include arms, abdomen, hips and thighs. A different site for injection should be used each day in order to reduce the likelihood of local irritation or pain as a result of the injection.
Patients should be instructed in self-injection techniques to assure the safe administration of Copaxone (see Copaxone Consumer Medicine Information).
Before injecting, the solution should be removed from refrigerated storage and left at room temperature for about 20 minutes to warm up.
Copaxone is intended for long-term treatment and its use should not be discontinued unless clearly indicated by a physician.
Copaxone pre-filled syringe contains no antimicrobial agent. It is for single use in one patient only. Discard any residue.

4.3 Contraindications

Copaxone is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

4.4 Special Warnings and Precautions for Use

Immediate post-injection reaction.

In placebo-controlled studies of up to 2 years duration with Copaxone 20 mg/mL, approximately 16% of patients given Copaxone and 4% given placebo experienced a constellation of symptoms immediately after injection. In a 12 month, placebo controlled study of Copaxone 40 mg/mL, approximately 2% of patients given Copaxone and none given placebo developed similar symptoms. Symptoms included: flushing, chest pain, palpitations, anxiety, dyspnoea, constriction of the throat, and urticaria. The symptoms were generally transient and self limited and did not require specific treatment. In general, these symptoms have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience one or several episodes of these symptoms. Whether or not any of these symptoms actually represent a specific syndrome is uncertain. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care.
Whether an immunologic or nonimmunologic mechanism mediates these episodes, or whether several similar episodes seen in a given patient have identical mechanisms, is unknown.
The treating physician should explain to the patient that a reaction (immediate postinjection reaction) associated with at least one of the following symptoms may occur within minutes of a Copaxone injection: vasodilatation (flushing), chest pain, dyspnoea, palpitations or tachycardia. The majority of these symptoms is short lived and resolves spontaneously without any sequelae.
Copaxone can cause post-injection reactions as well as anaphylactic reaction (see Section 4.8 (Adverse Effects (Undesirable Effects)).
Should a severe adverse event occur, the patient must immediately stop Copaxone treatment and contact his/her physician or any emergency doctor. Symptomatic treatment may be instituted at the discretion of the physician.

Chest pain.

In placebo-controlled studies of up to 2 years with Copaxone 20 mg/mL approximately 13% of patients given Copaxone and 6% given placebo experienced at least one episode of transient chest pain. In a 12 month, placebo controlled study with Copaxone 40 mg/mL approximately 2% of patients given Copaxone and 1% given placebo experienced at least one episode of chest pain. While some of these episodes occurred in the context of the immediate postinjection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was usually transient, often not associated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than one such episode, and episodes usually began at least 1 month after the initiation of treatment. The pathogenesis of this symptom is unknown.

Immune function.

As Copaxone is an antigenic material, it is possible that its use may lead to the induction of antibodies (see Section 5.1 Pharmacodynamic Properties).
As with all immunogenic medicines, hypersensitivity reactions may rarely occur.
Anaphylactic reactions may occur shortly following administration of Copaxone, even months or years after initiation of treatment (see Section 4.8 Adverse Effects (Undesirable Effects)). Cases with fatal outcomes have been reported. Some signs and symptoms of anaphylactic reactions may overlap with post-injection reactions. All patients receiving treatment with Copaxone and caregivers should be informed about the signs and symptoms specific for anaphylactic reactions and that they should seek immediate emergency medical care in case of experiencing such symptoms (see Section 4.8 Adverse Effects (Undesirable Effects)). If an anaphylactic reaction occurs, treatment with Copaxone must be discontinued (see Section 4.3 Contraindications).
Copaxone has not been studied in patients with a history of asthma, nor in patients under treatment for asthma. Particular caution is therefore advised regarding the use of Copaxone in such patients.
Although Copaxone is intended to minimise the autoimmune response to myelin, there is the possibility that chronic treatment with Copaxone might result in alteration of normal immune responses.

Injection site lipoatrophy and skin necrosis.

At injection sites, localised lipoatrophy and, rarely, injection site skin necrosis may occur. Skin necrosis has only been observed in the postmarketing setting. Localised lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy. To assist in possibly minimizing these events, the patient should be advised to follow proper injection technique and to rotate injection sites with each injection.

Use in renal impairment.

Renal function should be monitored in patients with impaired renal function.
The pharmacokinetics of Copaxone in patients with impaired renal function have not been determined. In patients with renal impairment, renal function should be monitored while they are treated with Copaxone. Whilst there is no evidence of glomerular deposition of immune complexes in patients, the possibility cannot be excluded. This drug should be administrated with care in patients with renal dysfunction.

Hepatic.

Rare cases of severe liver injury, including liver failure, hepatitis with jaundice, and extremely rare cases of fulminant hepatitis leading to liver transplant, have been reported with Copaxone during postmarketing experience in patients with and without relevant risk factors in their medical history, such as history of drug induced liver events with other disease modifying therapies (DMTs) indicated for the treatment of multiple sclerosis, concomitant treatment with drugs with known Drug Induced Liver Injury (DILI) risk or medical history of liver impairment. Hepatic adverse events have occurred from days to years after initiating treatment with Copaxone and with a similar profile with both dose regimens (20 mg/mL daily and 40 mg/mL TIW), suggesting idiosyncratic drug induced liver injury in most cases. Some cases, reported in patients who previously experienced liver injury during treatment with other immunomodulatory therapies used to treat multiple sclerosis, were suggestive of autoimmune hepatitis. Most events resolved with discontinuation of treatment and a relationship to Copaxone could not be excluded (see Section 4.8 Adverse Effects (Undesirable Effects), Post-marketing experience).
Caution is recommended when considering treatment with Copaxone in patients who have pre-existing liver disease or who have experienced liver injury previously during treatment with other drugs, including other disease modifying therapies (DMTs) for treatment of multiple sclerosis or with concomitant (DILI) risk drugs.
Prior to initiating treatment with Copaxone, serum aminotransferase, alkaline phosphatase and total bilirubin levels should be obtained (within 6 months) for all patients. Patients should be monitored during treatment for signs of hepatic injury. Evaluation of transaminases is recommended during treatment, as clinically relevant. Patients should be advised to immediately report any signs or symptoms of hepatotoxicity (e.g. jaundice, dark urine, abdominal pain, nausea, vomiting, loss of appetite, weight loss, and unusual fatigue). Discontinue treatment if clinically significant liver injury induced by Copaxone is suspected.

Use in the elderly.

Copaxone has not been studied specifically in elderly patients but safety data are reassuring for patients up to 65 years of age.

Paediatric use.

No prospective, randomised, controlled clinical trials or pharmacokinetic studies have been conducted in children or adolescents. However, limited published data suggest that the safety profile in adolescents from 12 to 18 years of age receiving Copaxone 20 mg subcutaneously every day is similar to that seen in adults. There is not enough information available on the use of Copaxone in children below 12 years of age to make any recommendation for its use. Therefore, Copaxone should not be used in this population.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Results from clinical trials do not suggest any significant interactions of Copaxone with therapies commonly used in MS patients. This includes the concurrent use of corticosteroids. Copaxone has not been formally evaluated in combination with interferon beta-1b. However, 10 patients who switched from therapy with interferon beta-1b to Copaxone have not reported any serious or unexpected adverse events thought to be related to treatment.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No evidence of reproductive toxicity was observed. In a fertility and reproductive study in rats, glatiramer acetate had no adverse effects on reproductive parameters at subcutaneous doses of up to 36 mg/kg/day, which is 15 times the daily therapeutic dose in humans expressed in terms of mg/m2.
(Category B1)
No adverse effects on embryofetal development occurred in reproduction studies in rats and rabbits receiving subcutaneous doses up to 37.5 mg/kg of glatiramer acetate during the period of organogenesis (15 and 28 times the daily human dose of 20 mg on a mg/m2 basis respectively).
To date, post-market information was received on more than 8,000 pregnancies, out of which 2000 were prospectively reported pregnancies with known outcome in patients exposed to conventional dose regimens of Copaxone. In this cohort, the reported rate of fetal loss was below 14% while congenital anomalies or disorders occurred in less than 3% of the pregnancies. These prevalence rates are within the range found in a normal population. However, since there are no adequate and well controlled studies in pregnant women, and because animal reproduction studies are not always predictive of human response, Copaxone should be used during pregnancy only if the benefits to the mother outweigh the potential risks to the fetus.
 There are no data on the effects of glatiramer acetate on milk production or on the presence of glatiramer acetate in human milk. The physicochemical properties and low oral absorption suggest that exposure of newborns/infants to glatiramer acetate via human breast milk is negligible.
Limited data in humans showed no negative effects of glatiramer acetate on breastfed infants. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for glatiramer acetate and any potential adverse effects on the breastfed infant from glatiramer acetate or from the underlying maternal condition.

4.7 Effects on Ability to Drive and Use Machines

Based on current data, no special caution is required for patients operating a car or using complex machinery.

4.8 Adverse Effects (Undesirable Effects)

Copaxone 20 mg/mL administered once daily.

The adverse event data in this section are derived from 5 pivotal, double-blind, placebo-controlled clinical trials which were conducted during pre-marketing and post-marketing periods in a total of 563 patients treated with Copaxone and 564 patients treated with placebo for up to 36 months. Three trials were conducted in RRMS and one trial in secondary progressive MS (SPMS). The fifth trial was in patients presenting with a first clinical event and MRI features suggestive of MS and included 243 patients treated with Copaxone and 238 patients treated with placebo.
In the 5 placebo-controlled clinical trials the most commonly observed adverse events occurring at an incidence of at least 10% with the use of Copaxone and at least 1.5 times higher than among placebo-treated patients were: injection site reactions, vasodilatation, rash, dyspnoea and chest pain.
Approximately 5% of the subjects receiving Copaxone discontinued treatment because of an adverse event. The adverse events most commonly associated with discontinuation were: injection site reactions, dyspnea, urticaria, vasodilatation and hypersensitivity.
Controlled clinical trials experience. The following table (Table 1) lists treatment-emergent signs and symptoms that occurred in at least 2% of patients treated with Copaxone 20 mg/mL in the placebo-controlled trials. These signs and symptoms were numerically more common in patients treated with Copaxone than in patients treated with placebo. Adverse events were usually mild in intensity.
The overall frequency of adverse events and the frequencies of individual adverse events were higher in patients treated with Copaxone for RRMS or SPMS, and lower in patients treated with Copaxone for a first clinical episode of MS.
Events which occurred only in 4-5 more subjects in the Copaxone group than in the placebo group (less than 1% difference), but for which a relationship to Copaxone could not be excluded, were arthralgia and herpes simplex.
Laboratory analyses were performed on all patients participating in the clinical program for Copaxone. Clinically significant laboratory values for haematology, chemistry and urinalysis were similar for both Copaxone and placebo groups in blinded clinical trials. No patient receiving Copaxone withdrew from any placebo-controlled trial because of abnormal laboratory findings which were assessed as possibly related to Copaxone. In one of the placebo-controlled trials, a transient elevation in eosinophils was shown after three months of Copaxone treatment in up to 7% of the patients which gradually declined while on treatment.
Data on adverse events occurring in the controlled clinical trials were analysed to evaluate differences based on sex. No clinically significant differences were identified. Ninety-six percent of patients in these clinical trials were Caucasian. This percentage is indicative of the higher representation of Caucasians in the MS population, even though it does not reflect the exact world racial distribution among MS patients. In addition, the vast majority of patients treated with Copaxone were between the ages of 18 and 45. Consequently, data are inadequate to perform an analysis of the adverse event incidence related to clinically relevant age subgroups.
Pre-marketing clinical trials experience with Copaxone 20 mg/mL. During the pre-marketing period, clinical trials were conducted in RRMS and SPMS, only some of which were placebo-controlled. At that time, Copaxone was administered to approximately 900 individuals who received at least one dose.
Similar types of events were grouped into standardised categories using COSTART dictionary terminology. All reported events occurring at least twice and potentially important events occurring once are listed below, except those too general to be informative, trivial events, and other events which occurred in at least 2% of treated patients and were present at equal or greater rates in the placebo group. Additional adverse events reported during the post-marketing period are also included.
Events are further classified within body system categories and listed in order of decreasing frequency using the following definitions. Frequent adverse events are defined as those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare adverse events are those occurring in less than 1/1,000 patients.

Body as a whole.

Frequent: injection site oedema, injection site atrophy, abscess, injection site hypersensitivity.
Infrequent: injection site haematoma, injection site fibrosis, moon face, cellulitis, generalised oedema, hernia, injection site abscess, serum sickness, suicide attempt, injection site hypertrophy, injection site melanosis, lipoma, photosensitivity reaction and injection site necrosis.

Cardiovascular.

Frequent: hypertension.
Infrequent: hypotension, midsystolic click, systolic murmur, atrial fibrillation, bradycardia, fourth heart sound, postural hypotension and varicose veins.

Digestive.

Infrequent: dry mouth, stomatitis, burning sensation on tongue, cholecystitis, colitis, oesophageal ulcer, oesophagitis, gastrointestinal carcinoma, gum haemorrhage, hepatomegaly, increased appetite, melaena, mouth ulceration, pancreas disorder, pancreatitis, rectal haemorrhage, tenesmus, tongue discolouration and duodenal ulcer.

Endocrine.

Infrequent: goiter, hyperthyroidism and hypothyroidism.

Gastrointestinal.

Frequent: bowel urgency, oral moniliasis, salivary gland enlargement, tooth caries and ulcerative stomatitis.

Haemic and lymphatic.

Infrequent: leukopenia, anaemia, cyanosis, eosinophilia, hematemesis, lymphoedema, pancytopenia and splenomegaly.

Metabolic and nutritional.

Infrequent: weight loss, alcohol intolerance, Cushing's syndrome, gout, abnormal healing and xanthoma.

Musculoskeletal.

Infrequent: arthritis, muscle atrophy, bone pain, bursitis, kidney pain, muscle disorder, myopathy, osteomyelitis, tendon pain and tenosynovitis.

Nervous.

Frequent: abnormal dreams, emotional lability and stupor.
Infrequent: aphasia, ataxia, convulsion, circumoral paraesthesia, depersonalisation, hallucinations, hostility, hypokinesia, coma, concentration disorder, facial paralysis, decreased libido, manic reaction, memory impairment, myoclonus, neuralgia, paranoid reaction, paraplegia, psychotic depression and transient stupor.

Respiratory.

Frequent: hyperventilation, hay fever.
Infrequent: asthma, pneumonia, epistaxis, hypoventilation and voice alteration.

Skin and appendages.

Frequent: eczema, herpes zoster, pustular rash, skin atrophy and warts.
Infrequent: dry skin, skin hypertrophy, dermatitis, furunculosis, psoriasis, angioedema, contact dermatitis, erythema nodosum, fungal dermatitis, maculopapular rash, pigmentation, benign skin neoplasm, skin carcinoma, skin striae and vesiculobullous rash.

Special senses.

Frequent: visual field defect.
Infrequent: dry eyes, otitis externa, ptosis, cataract, corneal ulcer, mydriasis, optic neuritis, photophobia and taste loss.

Urogenital.

Frequent: amenorrhoea, haematuria, impotence, menorrhagia, suspicious Papanicolaou smear, urinary frequency and vaginal haemorrhage.
Infrequent: vaginitis, flank pain (kidney), abortion, breast engorgement, breast enlargement, carcinoma in situ cervix, fibrocystic breast, kidney calculus, nocturia, ovarian cyst, priapism, pyelonephritis, abnormal sexual function and urethritis.

Copaxone 40 mg/mL administered three times per week.

The safety of Copaxone 40 mg/mL was assessed based on a double-blind, placebo-controlled clinical trial involving a total of 943 patients treated with Copaxone 40 mg/mL three times per week, and 461 patients treated with placebo for 12 months. Approximately 3% of patients treated with Copaxone 40 mg/mL discontinued treatment because of an adverse event.
Adverse drug reactions seen in patients treated with Copaxone 40 mg/mL were those already known and labelled for Copaxone 20 mg/mL daily and mostly reported at a similar frequency.
Injection site reactions were reported by 36% of the patients on Copaxone 40 mg/mL compared to 5% on placebo. Immediate post-injection reaction was reported by 8% of the patients on Copaxone 40 mg/mL compared to 2% on placebo.
A few specific adverse reactions are noted from an integrated safety analysis consisting of three studies that involved Copaxone 20 mg/mL once daily compared to Copaxone 40 mg/mL daily (two studies), and Copaxone 40 mg/mL 3 times a week compared to placebo. There was no direct comparison performed in a study between Copaxone 20 mg/mL daily with Copaxone 40 mg/mL 3 times a week. Only adverse events reported for the Copaxone 20 mg/mL daily, Copaxone 40 mg/mL 3 times a week and placebo groups are presented below.
During the double blind phase of the trials the incidence in subjects of hypersensitivity/ anaphylaxis was 0.6% on 20 mg/mL once daily, 0.7% on 40 mg/mL 3 times a week and 0.4% on placebo.
No injection site necrosis was reported with the 40 mg/mL 3 times a week. Injection site atrophy occurred in 1.1% of patients on 20 mg/mL daily, 0.5% on 40 mg/mL 3 times a week and 0% on placebo.
During the double blind phase of the trials the incidence in subjects of skin erythema was 3.3% on 20 mg/mL once daily, 2.1% on 40 mg/mL 3 times a week and 0% on placebo, while for pain in extremity it was 5.2% on 20 mg/mL daily, 2.1% on 40 mg/mL 3 times a week and 1.7% on placebo.
During the double blind phase of the trials the incidence in subjects of drug induced liver injury was 0.2% on 20 mg/mL once daily, 0.1% on 40 mg/mL 3 times a week and 0% on placebo, while for toxic hepatitis it was 0% on 20 mg/mL daily, 0.1% on 40 mg/mL 3 times a week and 0% on placebo: hepatic steatosis had an incidence 0.2% in both Copaxone groups and 0% on placebo.
Controlled clinical trial experience. The following table (Table 2) lists treatment-emergent signs and symptoms that occurred in at least 2% of patients treated with Copaxone 40 mg/mL in the blinded, placebo-controlled trial. These signs and symptoms were numerically more common in patients treated with Copaxone 40 mg/mL than in patients treated with placebo. Adverse reactions were usually mild in intensity.

Post-marketing experience.

Postmarketing experience has shown an adverse event profile similar to that presented above. Reports of adverse events occurring under treatment with Copaxone injection 20 mg/mL not mentioned above that have been received since market introduction and that may or may not have causal relationship to the drug are listed below. As these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body as a whole.

Sepsis; LE syndrome; hydrocephalus; enlarged abdomen; injection site hypersensitivity; allergic reaction; anaphylactic reaction.

Immune system.

Anaphylactic reactions may occur shortly following administration of glatiramer acetate, even months or years after initiation of treatment with a frequency uncommon (see Section 4.4 Special Warnings and Precautions for Use).

Cardiovascular system.

Thrombosis; peripheral vascular disease; pericardial effusion; myocardial infarct; deep thrombophlebitis; coronary occlusion; congestive heart failure; cardiomyopathy; cardiomegaly; arrhythmia; angina pectoris.

Digestive system.

Tongue oedema; stomach ulcer; haemorrhage; liver function abnormality; liver damage; hepatitis; eructation; cirrhosis of the liver; cholelithiasis.

Haemic and lymphatic system.

Thrombocytopenia; lymphoma-like reaction; acute leukaemia.

Metabolic and nutritional disorders.

Hypercholesterolaemia.

Musculoskeletal system.

Rheumatoid arthritis; generalised spasm.

Nervous system.

Myelitis; meningitis; CNS neoplasm; cerebrovascular accident; brain oedema; abnormal dreams; aphasia; convulsion; neuralgia.

Respiratory system.

Pulmonary embolus; pleural effusion; carcinoma of lung; hay fever.

Special senses.

Glaucoma; blindness; visual field defect.

Urogenital system.

Urogenital neoplasm; urine abnormality; ovarian carcinoma; nephrosis; kidney failure; breast carcinoma; bladder carcinoma; urinary frequency.
Rare cases of severe liver injury (including liver failure, hepatitis with jaundice and fulminant hepatitis leading to liver transplant) have been reported with Copaxone in post-marketing experience. Most instances of severe liver injury resolved with discontinuation of treatment. Hepatic events have occurred from days to years after initiating treatment with Copaxone.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

There are 13 reports to date of overdose with Copaxone which were confirmed by health care professionals. Most cases concern 2 or 3 injections given on the same day. The largest dose of Copaxone that has been administered is 300 mg on a single occasion. No adverse reactions occurred and the patient continued treatment.
There is no specific antidote. Treatment of overdose consists of discontinuation of Copaxone, along with monitoring the patient for at least 10 hours and the institution of appropriate symptomatic and supportive therapy. Contact the Poisons Information Centre for advice on the management of overdosage.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

The precise mechanism by which glatiramer acetate exerts its effects in patients with multiple sclerosis (MS) is unknown. It is thought to act by modifying immune processes that are currently held to be responsible for the pathogenesis of MS. This view of glatiramer acetate derives from knowledge that it reduces the incidence and severity of experimental allergic encephalomyelitis (EAE), a condition induced in several animal species through immunisation with CNS-derived material containing myelin and often used as an experimental animal model of MS.

Clinical trials.

Relapsing remitting multiple sclerosis.

Copaxone 20 mg/mL administered once daily.

Evidence supporting the effectiveness of Copaxone 20 mg/mL for decreasing the frequency of relapses in patients with relapsing remitting multiple sclerosis (RRMS) derives from two placebo controlled trials, both of which used a Copaxone dose of 20 mg/day.
One trial enrolled 50 patients who were randomised to receive daily doses of Copaxone 20 mg or placebo subcutaneously. Patients were diagnosed with RRMS by standard criteria and had at least two exacerbations during the two years immediately preceding enrolment. Patients were ambulatory, as evidenced by a score of no more than 6 on the Kurtzke Expanded Disability Scale Score (EDSS), a standard scale ranging from 0 (normal) to 10 (death due to MS). A score of 6 is defined as one at which a patient is still ambulatory with assistance; a score of 7 means the patient must use a wheelchair.
Patients were reviewed every 3 months for two years, as well as within several days of a presumed exacerbation. In order for an exacerbation to be confirmed, a blinded neurologist had to document objective neurologic signs, as well as document the existence of other criteria (e.g. the persistence of the lesion for at least 48 hours).
The protocol-specified primary outcome measure was the proportion of patients in each treatment group who remained exacerbation free for the two year trial, but two other important outcomes were also specified as endpoints: the frequency of relapses during the trial and the change in number of relapses compared to the previous two years.
The following table (Table 3) presents the results of analyses of the three outcomes described above, as well as several other secondary measures. These analyses are based on the intent to treat population (i.e. all patients who received at least one dose of treatment and who had at least one on treatment assessment).
The second trial was of similar design to the first study. A total of 251 patients were enrolled. The primary outcome measure was the mean 2 year relapse rate. Table 4 presents the results of the analysis of this outcome for the intent to treat population, as well as other secondary measures.
Results also showed that glatiramer acetate reactive antibodies were present in all treated patients' sera, with maximal levels attained after a duration of 3-4 months. Thereafter antibody levels slowly declined and stabilised at a level slightly higher than baseline.
The antibody profile in patients who experienced relapses was similar to that observed in all patients and the occurrence of relapses was independent of glatiramer acetate antibody production. The occurrence of systemic reactions had no correlation to glatiramer acetate antibody production.
Analysis of glatiramer acetate antibody type revealed that specific IgG and not IgE antibodies were produced following chronic treatment with Copaxone. The ability of glatiramer acetate antibodies to neutralise the biological activity of glatiramer acetate was investigated in several in vitro and in vivo systems. No neutralising activity was exhibited by a variety of monoclonal and polyclonal glatiramer acetate antibodies, including those formed during long-term administration to MS patients.
Thus antibody formation is unlikely to be associated with either short or long-term safety issues and is unlikely to affect the clinical efficacy or the biological activity of Copaxone.
In both studies, Copaxone exhibited a clear beneficial and statistically significant effect on relapse rate and it is on this basis that Copaxone is considered effective. Response rates were apparently better for those patients where therapy was initiated early in the course of the disease. A correlation between reduction in relapse frequency alone and a decreased risk of future disability remains to be established.

Copaxone 40 mg/mL administered three times per week.

Evidence supporting the effectiveness of Copaxone 40 mg/mL injection administered subcutaneously three times a week in decreasing the frequency of relapses derives from one 12-month placebo-controlled study. The primary outcome measure was the total number of confirmed relapses. The effect of Copaxone on several magnetic resonance imaging (MRI) variables including number of new or enlarging T2 lesions and number of enhancing lesions on T1 weighted images was also measured at months 6 and 12.
A total of 1404 patients were randomized in a 2:1 ratio to receive either Copaxone 40 mg/mL (n = 943) or placebo (n = 461). Both treatment groups were comparable with respect to baseline demographics, MS disease characteristics and MRI parameters. Patients had a median of 2.0 relapses in the 2 years prior to screening.
The following table (Table 5) presents the values for the primary and secondary outcome measures for the intent to treat population.
Single clinical event suggestive of multiple sclerosis.

Copaxone 20 mg/mL administered once daily.

One placebo-controlled study involving 481 patients (Copaxone n = 243, placebo n = 238) was performed in patients with a well-defined, single, unifocal neurological manifestation and MRI features highly suggestive of MS (at least two cerebral lesions on the T2 weighted MRI above 6 mm diameter). Any disease other than MS that could better explain signs and symptoms of the patient had to be excluded.
During the placebo-controlled period of up to three years, Copaxone delayed the progression from the first clinical event to clinically definite multiple sclerosis (CDMS) according to Poser criteria in a statistically significant and clinically meaningful manner, corresponding to a risk reduction of 45% (hazard ratio = 0.55; 95% CI (0.40; 0.77), p-value = 0.0005). Copaxone prolonged the time to CDMS by 386 (115%) days, from 336 days in the placebo group to 722 days in the Copaxone group (based on the 25th percentile; Kaplan-Meier estimates). The robustness of the results was confirmed in the completers and per protocol cohorts.
The favourable effect of treatment with Copaxone over placebo was also demonstrated in two secondary MRI endpoints. The first, number of new T2 lesions at last observed value (LOV) of the placebo controlled phase was statistically significantly (p-value < 0.0001) lower for patients on Copaxone, demonstrating a treatment effect of 58% for Copaxone over placebo. The mean (SD) number of new T2 lesions was 0.7 (1.7) in the Copaxone group and 1.8 (3.6) in the placebo group. The second MRI endpoint, baseline adjusted T2 lesion volume at LOV of the placebo controlled phase, showed a statistically significant (p-value = 0.0002) reduction of 25% in T2 lesion volume. The mean (SD) change from baseline in total T2 lesion volume was 1.2 (2.6) mL in the Copaxone group and 2.6 (3.9) mL in the placebo group. The clinical secondary endpoint showed that the proportion of patients who converted to CDMS (43% of the placebo patients compared to 25% of the Copaxone patients) was statistically significantly (p-value < 0.0001) lower for patients on Copaxone, demonstrating a treatment effect of 59% in favour of Copaxone.
Subgroup analyses of the risk in three years for progression to CDMS according to baseline factors demonstrated evidence of efficacy in all subgroups evaluated. A significant risk reduction of 39% and 54% was obtained for patients with and without corticosteroid treatment for the initial attack, respectively, and 66% risk reduction was demonstrated for patients with a unifocal optic manifestation at the initial attack. A significant risk reduction of 71% for patients with baseline T1 gadolinium enhancement and 58% for patients with 9 or more T2 lesions at baseline was obtained. Copaxone was also effective in patients with no enhancement at baseline who demonstrated a significant risk reduction of 44%.

5.2 Pharmacokinetic Properties

There is no information regarding the absorption, distribution, metabolism or excretion profile of glatiramer acetate in humans as there is currently no direct and sensitive analytical method for measuring glatiramer acetate in biological fluids. Therefore, all pharmacokinetic studies have been conducted in animals using radiolabelled glatiramer acetate. The methodology is limited because the radiolabel dissociates rapidly from glatiramer acetate and re-associates with other macromolecules. However, the studies indicate that glatiramer acetate is readily absorbed; repetitive dosing has no effect on absorption; Cmax and AUC are linearly dependent across the administered glatiramer acetate dose range and there is no evidence of any tissue accumulation of glatiramer acetate.
Results from studies with human tissues reveal rapid hydrolysis of glatiramer acetate by both subcutaneous and muscle tissues. In contrast, plasma has a "stabilising" effect on glatiramer acetate, which may be explained by the observation that it is 97.5% bound to plasma proteins in vitro. Based on results of animal studies and on the hydrolysis of glatiramer acetate by human tissues, it may be concluded that glatiramer acetate is extensively degraded at the site of subcutaneous injection. It has not been possible to determine the excretory fate of glatiramer acetate or its metabolites as they cannot be distinguished from naturally occurring amino acids or peptides.
Although the concentration of glatiramer acetate in blood cannot be determined directly, three lines of evidence support it being bioavailable to the immune system, which is the site of its therapeutic activity:
1. Clinical efficacy in patients with relapsing remitting multiple sclerosis.
2. Formation of antibodies to glatiramer acetate in treated patients.
3. Decline in the peripheral blood mononuclear cell proliferative response to glatiramer acetate following chronic exposure.

5.3 Preclinical Safety Data

Genotoxicity.

Glatiramer acetate was not mutagenic in vitro, but a clastogenic effect was observed in two separate in vitro assays in human lymphocytes. There was no evidence of clastogenicity in a mouse bone marrow micronucleus assay in vivo.

Carcinogenicity.

In a 2-year carcinogenicity study, repeated subcutaneous administration of glatiramer acetate to male mice at doses 12 times the daily human therapeutic dose on a mg/m2 basis was associated with the development of skin and subcutis sarcomas. This effect may have been associated with persistent tissue damage at injection sites, which tended to be more common and was of greater severity in males. The incidence of skin sarcoma was not increased in female mice at doses up to 12 times the daily human therapeutic dose on a mg/m2 basis. In a 2-year carcinogenicity study in rats, subcutaneous administration of glatiramer acetate at 12 times the daily therapeutic human dose on a mg/m2 basis was associated with an increased incidence of benign adrenal phaeochromocytomas in males only; this effect was not seen at 6 times the daily human dose and was within the historical control values for the testing laboratory. The possible relevance of these findings to humans is not known.

6 Pharmaceutical Particulars

6.1 List of Excipients

Mannitol, water for injections.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store Copaxone at 2°C to 8°C. Refrigerate, do not freeze. In the event of refrigeration being unavailable, Copaxone may be stored below 25°C on one occasion for up to one month. After this one month period, if the Copaxone pre-filled syringes have not been used and are still in their original packaging, they must be returned to storage in a refrigerator (2°C to 8°C). Keep the pre-filled syringe in the outer carton when not injecting, in order to protect from light.

6.5 Nature and Contents of Container

Copaxone 40 mg/mL is supplied as a sterile pre-filled syringe fitted with staked ½ inch needle containing 40 mg glatiramer acetate, 40 mg mannitol and water for injections.
Copaxone 40 mg/mL is supplied in packs of 12 pre-filled syringes for subcutaneous injection.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Chemical structure.

The structural formula of glatiramer acetate is shown below:
Poly [L-Glu13-15, L-Ala39-46, L-Tyr8.6-10, L-Lys30-37].n(CH3CO2H).
n = 15 to 24 units per 100 amino acid residues.
The superscripts in the formula above represent the molar fraction percent range of the amino acid residues comprising the various polypeptide species in glatiramer acetate where the sequence of the amino acid residues varies among the individual species.
The average molecular weight of glatiramer acetate is 5000 to 9000 Daltons.
Glatiramer acetate is a white to slightly yellowish lyophilised material which is sparingly soluble in water and insoluble in acetone.
The pH of a 0.5% solution in water is in the range of 5.5 to 7.0 and an osmolarity of about 265 mOsmol/L and 300 mOsmol/L for the 20 mg/mL and 40 mg/mL, respectively.

CAS number.

CAS registry number: 147245-92-9.
CAS registry number of the free base: 28704-27-0.

7 Medicine Schedule (Poisons Standard)

Schedule 4 Prescription Only Medicine.

Summary Table of Changes